Regeneron Pharmaceuticals, Inc. acquired a significant new investment from Fox Run Management L.L.C., adding 1,734 shares worth about $1.1 million. The biopharmaceutical giant reported an impressive ...

Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...

Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.

Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...

Single Ventricle Heart Disease is a rare congenital heart defect where one of the heart's ventricles is underdeveloped or ...